Spyre Therapeutics, Inc. has signed a big deal to sell 4,117,648 shares for $85 each.

Oct 7, 2026, 8:05 AM ETNew sharesRead the original at SEC EDGAR

Neutral

The cash can fund Spyre's drug programs, but the new shares give current owners a smaller piece. The filing shows both effects and does not establish which will matter more.

SYRE · Spyre Therapeutics, Inc.

AI read · Neutral

The AI's read

The cash gives Spyre more room to advance its digestive, joint, and skin treatments, including a program for a painful skin disease. But issuing new shares gives current owners a smaller slice. The filing does not show which effect will matter more.

Get alerts for SYRE

Follow Spyre Therapeutics, Inc. (SYRE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SYRE

Free on the App Store and Google Play, or on the web.